Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

PEG10 is associated with treatment-induced neuroendocrine prostate cancer.

Kim S, Thaper D, Bidnur S, Toren P, Akamatsu S, Bishop JL, Colins C, Vahid S, Zoubeidi A.

J Mol Endocrinol. 2019 Jul 1;63(1):39-49. doi: 10.1530/JME-18-0226.

PMID:
31013476
2.

Complete Genome Assembly of Yersinia pseudotuberculosis IP2666pIB1.

Zoubeidi A, Schwiesow L, Auerbuch V, Lam HN.

Microbiol Resour Announc. 2019 Feb 14;8(7). pii: e01592-18. doi: 10.1128/MRA.01592-18. eCollection 2019 Feb.

3.

Biological Evolution of Castration-resistant Prostate Cancer.

Davies A, Conteduca V, Zoubeidi A, Beltran H.

Eur Urol Focus. 2019 Mar;5(2):147-154. doi: 10.1016/j.euf.2019.01.016. Epub 2019 Feb 14. Review.

PMID:
30772358
4.

ONECUT2 is a driver of neuroendocrine prostate cancer.

Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH.

Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6.

5.

Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells.

Jain P, Clermont PL, Desmeules F, Zoubeidi A, Neveu B, Pouliot F.

Int J Mol Sci. 2019 Jan 8;20(1). pii: E216. doi: 10.3390/ijms20010216.

6.

Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.

Thaper D, Vahid S, Kaur R, Kumar S, Nouruzi S, Bishop JL, Johansson M, Zoubeidi A.

Sci Rep. 2018 Nov 23;8(1):17307. doi: 10.1038/s41598-018-35612-z.

7.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

8.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889.

9.

Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19.

Hua JT, Ahmed M, Guo H, Zhang Y, Chen S, Soares F, Lu J, Zhou S, Wang M, Li H, Larson NB, McDonnell SK, Patel PS, Liang Y, Yao CQ, van der Kwast T, Lupien M, Feng FY, Zoubeidi A, Tsao MS, Thibodeau SN, Boutros PC, He HH.

Cell. 2018 Jul 26;174(3):564-575.e18. doi: 10.1016/j.cell.2018.06.014. Epub 2018 Jul 19.

PMID:
30033362
10.

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC.

Gigascience. 2018 Jun 1;7(6). doi: 10.1093/gigascience/giy050.

11.

Co-targeting driver pathways in prostate cancer: two birds with one stone.

Zoubeidi A, Gleave ME.

EMBO Mol Med. 2018 Apr;10(4). pii: e8928. doi: 10.15252/emmm.201808928. No abstract available.

12.

Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.

Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H, Wang Y, Zhang F, Qu S, Zhang F, Haegert AM, Gout PW, Zoubeidi A, Collins C, Gleave ME, Lin D, Wang Y.

Eur Urol. 2018 Jun;73(6):949-960. doi: 10.1016/j.eururo.2018.02.019. Epub 2018 Mar 12.

13.

Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.

Ci X, Hao J, Dong X, Choi SY, Xue H, Wu R, Qu S, Gout PW, Zhang F, Haegert AM, Fazli L, Crea F, Ong CJ, Zoubeidi A, He HH, Gleave ME, Collins CC, Lin D, Wang Y.

Cancer Res. 2018 May 15;78(10):2691-2704. doi: 10.1158/0008-5472.CAN-17-3677. Epub 2018 Feb 27.

14.

Cellular plasticity and the neuroendocrine phenotype in prostate cancer.

Davies AH, Beltran H, Zoubeidi A.

Nat Rev Urol. 2018 May;15(5):271-286. doi: 10.1038/nrurol.2018.22. Epub 2018 Feb 20. Review.

PMID:
29460922
15.

SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1.

Peacock JW, Takeuchi A, Hayashi N, Liu L, Tam KJ, Al Nakouzi N, Khazamipour N, Tombe T, Dejima T, Lee KC, Shiota M, Thaper D, Lee WC, Hui DH, Kuruma H, Ivanova L, Yenki P, Jiao IZ, Khosravi S, Mui AL, Fazli L, Zoubeidi A, Daugaard M, Gleave ME, Ong CJ.

EMBO Mol Med. 2018 Feb;10(2):219-238. doi: 10.15252/emmm.201707689.

16.

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16. Review.

17.

Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia.

Melong N, Steele S, MacDonald M, Holly A, Collins CC, Zoubeidi A, Berman JN, Dellaire G.

Sci Rep. 2017 Oct 31;7(1):14698. doi: 10.1038/s41598-017-14413-w.

18.

LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.

Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, Karnes RJ, Chadwick D, van der Kwast T, Boutros PC, Arrowsmith CH, Feng FY, Joshua AM, Zoubeidi A, Cai C, He HH.

Cancer Res. 2017 Oct 15;77(20):5479-5490. doi: 10.1158/0008-5472.CAN-17-0496. Epub 2017 Sep 15.

19.

Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.

Ketola K, Munuganti RSN, Davies A, Nip KM, Bishop JL, Zoubeidi A.

Clin Cancer Res. 2017 Nov 15;23(22):6923-6933. doi: 10.1158/1078-0432.CCR-17-0901. Epub 2017 Sep 12.

20.

Patient-derived xenografts: A platform for accelerating translational research in prostate cancer.

Davies AH, Wang Y, Zoubeidi A.

Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):17-24. doi: 10.1016/j.mce.2017.03.013. Epub 2017 Mar 15. Review.

PMID:
28315377
21.

Targeting Lyn regulates Snail family shuttling and inhibits metastasis.

Thaper D, Vahid S, Nip KM, Moskalev I, Shan X, Frees S, Roberts ME, Ketola K, Harder KW, Gregory-Evans C, Bishop JL, Zoubeidi A.

Oncogene. 2017 Jul 13;36(28):3964-3975. doi: 10.1038/onc.2017.5. Epub 2017 Mar 13.

PMID:
28288135
22.

MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2.

Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson AR, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, Ross AE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubeidi A, Goodall GJ, Feng FY, Butler LM, Tilley WD, Selth LA.

Cancer Res. 2017 Feb 15;77(4):1021-1034. doi: 10.1158/0008-5472.CAN-16-2529. Epub 2016 Dec 23.

23.

Clusterin as a therapeutic target.

Wilson MR, Zoubeidi A.

Expert Opin Ther Targets. 2017 Feb;21(2):201-213. doi: 10.1080/14728222.2017.1267142. Epub 2016 Dec 16. Review.

PMID:
27978767
24.

Chaperoning the Cancer: The Proteostatic Functions of the Heat Shock Proteins in Cancer.

Vahid S, Thaper D, Zoubeidi A.

Recent Pat Anticancer Drug Discov. 2017;12(1):35-47. doi: 10.2174/1574892811666161102125252. Review.

PMID:
27809750
25.

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.

Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26.

26.

BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer.

Luk IS, Shrestha R, Xue H, Wang Y, Zhang F, Lin D, Haegert A, Wu R, Dong X, Collins CC, Zoubeidi A, Gleave ME, Gout PW, Wang Y.

Clin Cancer Res. 2017 Mar 15;23(6):1542-1551. doi: 10.1158/1078-0432.CCR-16-0718. Epub 2016 Sep 23.

27.

Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer.

Vahid S, Thaper D, Gibson KF, Bishop JL, Zoubeidi A.

Sci Rep. 2016 Aug 24;6:31842. doi: 10.1038/srep31842.

28.

Corrigendum re: "Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer" [Eur Urol 2014;66:145-55].

Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME.

Eur Urol. 2016 Jul;70(1):e27-e28. doi: 10.1016/j.eururo.2016.03.014. Epub 2016 Mar 31. No abstract available.

PMID:
27302299
29.

A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.

Selth LA, Das R, Townley SL, Coutinho I, Hanson AR, Centenera MM, Stylianou N, Sweeney K, Soekmadji C, Jovanovic L, Nelson CC, Zoubeidi A, Butler LM, Goodall GJ, Hollier BG, Gregory PA, Tilley WD.

Oncogene. 2017 Jan 5;36(1):24-34. doi: 10.1038/onc.2016.185. Epub 2016 Jun 6.

PMID:
27270433
30.

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.

Toren P, Kim S, Johnson F, Zoubeidi A.

PLoS One. 2016 Apr 5;11(4):e0152861. doi: 10.1371/journal.pone.0152861. eCollection 2016.

31.

The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells.

Davies AH, Zoubeidi A.

Stem Cells Int. 2016;2016:4829602. doi: 10.1155/2016/4829602. Epub 2016 Jan 10. Review.

32.

Erratum: Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.

Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Languino LR.

Oncotarget. 2015 Oct 20;6(32):34038. doi: 10.18632/oncotarget.6187. No abstract available.

33.

Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.

Li J, Karki A, Hodges KB, Ahmad N, Zoubeidi A, Strebhardt K, Ratliff TL, Konieczny SF, Liu X.

Mol Cell Biol. 2015 Dec;35(24):4185-98. doi: 10.1128/MCB.00825-15. Epub 2015 Oct 5.

34.

The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, Brahmbhatt S, Bell R, Adomat H, Kawai Y, Xue H, Dong X, Fazli L, Tsai H, Lotan TL, Kossai M, Mosquera JM, Rubin MA, Beltran H, Zoubeidi A, Wang Y, Gleave ME, Collins CC.

Cell Rep. 2015 Aug 11;12(6):922-36. doi: 10.1016/j.celrep.2015.07.012. Epub 2015 Jul 30.

35.

A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor.

Xia Y, Wang M, Beraldi E, Cong M, Zoubeidi A, Gleave M, Peng L.

Anticancer Agents Med Chem. 2015;15(10):1333-40.

PMID:
26081200
36.

Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.

Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Languino LR.

Oncotarget. 2015 Jun 10;6(16):14318-28. Erratum in: Oncotarget. 2015 Oct 20;6(32):34038.

37.

Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.

Bishop JL, Davies A, Ketola K, Zoubeidi A.

Endocr Relat Cancer. 2015 Jun;22(3):R165-82. doi: 10.1530/ERC-15-0137. Epub 2015 May 1. Review.

PMID:
25934687
38.

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.

Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, Kuruma H, Gleave ME, Zoubeidi A.

Oncotarget. 2015 Apr 20;6(11):9086-98.

39.

A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.

Fokidis HB, Yieng Chin M, Ho VW, Adomat HH, Soma KK, Fazli L, Nip KM, Cox M, Krystal G, Zoubeidi A, Tomlinson Guns ES.

J Steroid Biochem Mol Biol. 2015 Jun;150:35-45. doi: 10.1016/j.jsbmb.2015.03.006. Epub 2015 Mar 19.

PMID:
25797030
40.

Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.

Lelj-Garolla B, Kumano M, Beraldi E, Nappi L, Rocchi P, Ionescu DN, Fazli L, Zoubeidi A, Gleave ME.

Mol Cancer Ther. 2015 May;14(5):1107-16. doi: 10.1158/1535-7163.MCT-14-0866. Epub 2015 Mar 4.

41.

Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.

Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, Al Nakouzi N, Mo F, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Wang Y, Collins CC, Zoubeidi A, Gleave M.

Clin Cancer Res. 2015 Apr 1;21(7):1675-87. doi: 10.1158/1078-0432.CCR-14-1108. Epub 2015 Jan 29.

42.

Targeting heat shock proteins in metastatic castration-resistant prostate cancer.

Azad AA, Zoubeidi A, Gleave ME, Chi KN.

Nat Rev Urol. 2015 Jan;12(1):26-36. doi: 10.1038/nrurol.2014.320. Epub 2014 Dec 16. Review.

PMID:
25512207
43.

Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival.

Zhang F, Kumano M, Beraldi E, Fazli L, Du C, Moore S, Sorensen P, Zoubeidi A, Gleave ME.

Nat Commun. 2014 Dec 12;5:5775. doi: 10.1038/ncomms6775.

44.

Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.

Munuganti RS, Hassona MD, Leblanc E, Frewin K, Singh K, Ma D, Ban F, Hsing M, Adomat H, Lallous N, Andre C, Jonadass JP, Zoubeidi A, Young RN, Guns ET, Rennie PS, Cherkasov A.

Chem Biol. 2014 Nov 20;21(11):1476-85. doi: 10.1016/j.chembiol.2014.09.012.

45.

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.

Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, Zoubeidi A.

Oncotarget. 2015 Jan 1;6(1):234-42.

46.

Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.

Toren PJ, Kim S, Pham S, Mangalji A, Adomat H, Guns ES, Zoubeidi A, Moore W, Gleave ME.

Mol Cancer Ther. 2015 Jan;14(1):59-69. doi: 10.1158/1535-7163.MCT-14-0521. Epub 2014 Oct 28.

47.

Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.

Pham S, Deb S, Ming DS, Adomat H, Hosseini-Beheshti E, Zoubeidi A, Gleave M, Guns ES.

J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:436-44. doi: 10.1016/j.jsbmb.2014.09.004. Epub 2014 Sep 6.

PMID:
25201454
48.

Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.

Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, Gleave ME, Zoubeidi A.

Eur Urol. 2015 Jun;67(6):986-990. doi: 10.1016/j.eururo.2014.08.006. Epub 2014 Aug 20.

PMID:
25151012
49.

Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.

Lamoureux F, Baud'huin M, Ory B, Guiho R, Zoubeidi A, Gleave M, Heymann D, Rédini F.

Oncotarget. 2014 Sep 15;5(17):7805-19.

50.

Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer.

Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, Fazli L, Lamoureux F, Gust KM, Cox ME, Bishop JL, Zoubeidi A.

Oncogenesis. 2014 Aug 18;3:e115. doi: 10.1038/oncsis.2014.30.

Supplemental Content

Loading ...
Support Center